Riperidone

PreclinicalSmall molecule

UUniversity of Alabama at Birmingham

Riperidone is one of 13 small molecule programs targeting Suicidal Ideation. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Suicidal IdeationActive, not recruiting

Suicidal IdeationPreclinical

Active, not recruiting

Competition

Competitive Landscape

19 competitors in Suicidal Ideation

#DrugCompanyPhaseTrials

Ketalar

AAultman Health Foundation

Approved

13 2

Minipress

Pfizer

Approved

1 3

Versed

CConrado Roberto Hoffmann Filho

Approved

2 4

Ketalar

Boehringer Ingelheim

Phase 3

6 5

Intranasal Ketamine

JJavelin Pharmaceuticals

Phase 3

1 6

Uridine

UUniversity of Utah

Approved

1 7

Zolpidem CR

MMassachusetts General Hospital

Approved

1 8

Cesamet

BBausch Health Americas, Inc.

Phase 2

1 9

Lurasidone HC1

Sumitomo Pharma America, Inc.

Phase 3

2 10

Psilocybin

COMPASS Pathways

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Suicidal Ideation1 trial

Impulsivity and Thought Process Disorder in Patients With Active Suicidal Ideation and Depression

Withdrawn·UUniversity of Alabama at Birmingham·N/A·NCT01770600

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Riperidone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Riperidone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Riperidone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Alabama at Birmingham company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Alabama at Birmingham

Riperidone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Suicidal Ideation1 trial

References

Drug Info

Quick Facts

Related News